Abstract: A process for separating bifunctional perfluoropolyethers (PFPEs) having two terminations —CH2OH from their mixtures with monofunctional PFPEs with one termination —CH2OH, of general formula X1—O—Rf—Y??(I) wherein Rf is a perfluoropolyoxyalkylene chain having a number average molecular weight of 500-10,000; X1 and Y are end groups selected from —CFXCH2OH (wherein X is F or CF3), —CF3, —CF2Cl, —CF2CF2Cl, —C3F6Cl, —CF2Br, —CF2CF3, wherein at least one of the two end groups is —CFXCH2OH, said process comprising the steps of: a) addition of the PFPE mixture to an adsorbing solid phase, under stirring; b) filtration of the mixture obtained in a): c) addition to the solid phase filtered in b), of a PFPE mixture having an average functionality higher than that of the PFPE mixture of the liquid filtered in b); c2) filtration of the mixture obtained in c); and subsequent treatment of the solid phase separated in c2) with a polar solvent obtaining a liquid containing the PFPE having high functionality.

Abstract: Process for the perfluoropolyether preparation having reactive end groups —CH2NH2, —CHO, —CH2OH, by reduction of the corresponding perfluoropolyethers having —CN, —COCl, —CHO end groups by using gaseous hydrogen in the presence of a catalyst constituted by Pd, Rh, or Ru, supported on solid metal fluorides, at a temperature from 20° C. to 150° C. and under a pressure between 1 and 50 atm.

Abstract: An infusion device comprises a pusher for a plunger of a syringe containing a liquid to be infused. A load cell measures the push force. An encoder associated to a motor commanding the pusher measures the displacement of the pusher. A controller signals an alarm when the ratio between the variation of the push force and the displacement exceeds a predetermined threshold. The device, which serves for infusing an anticoagulant into an extracorporeal blood circuit in a dialysis apparatus, is able to signal an onset of an anomalous situation of lack of infusion in good time.

Abstract: A process comprises the phases of: activating a pusher, which exerts a push force on a plunger of a syringe containing the infusion liquid; measuring the push force by means of a load cell; comparing the push force with a maximum threshold; halting the pusher when the maximum threshold is exceeded; after a predetermined pause, restarting the pusher and emitting a consent signal indicating correct loading of the syringe if, within a certain time from the restart, the push force again exceeds the maximum threshold. The infusion device serves to inject an anticoagulant into an extracorporeal blood circuit.

Abstract: Cyclic phosphazene compounds of formula (I): wherein: Q is a cyclic compound of formula: A is an end group of the —OCF2X, —OC2F4X, —OC3F6X type, wherein X=F, Cl, H; Rf and R?f are (per)fluoropolyoxyalkylene chains having a number average molecular weight in the range 280-5,000.

Abstract: A process for the preparation of perfluoropolyethers of formula: T-CFX?—O—Rf—CFX—COF??(I) wherein: T=COF, F, C1-C3 perfluoroalkyl; X, X?=—F, —CF3; Rf=—(C2F4O)m(CF2CF(CF3)O)n(CF2O)p(CF(CF3)O)q—, the sum n+m+p+q ranges from 2 to 200, by reduction with hydrogen of the corresponding peroxidic perfluoropolyethers, in the presence of a catalyst formed by metals of the VIII group supported on metal fluorides, at a temperture from 20° C. to 140° C., and at a pressure between 1 and 50 atm.

Abstract: A description is given of a method of monitoring the operationality of a flow cut-off member for an extracorporeal fluid circuit. Also described is a system for arresting the flow of blood that implements this monitoring method. The system has a flow cut-off member active on a radially deformable length of tube forming part of the circuit, and a unit capable of causing a movement of a movable portion of the cut-off member towards a closed condition. The system detects when the movable portion passes through a first predetermined position and determines the value assumed by a dynamic parameter associated with the motion of the movable portion at the first predetermined position. The system further checks that this value is within a predetermined criterion of acceptability. Lastly, a blood treatment appliance is described that implements the described method and system.

Abstract: The invention relates to an extracorporeal blood treatment machine in which a blood circuit (3) is equipped with an inlet line leading to a filtration unit (2) and with an outlet line (3b) from the filtration unit; a fluid circuit comprises an inlet line (4a) leading to the filtration unit and an outlet line (4b) from the filtration unit so as to allow a fluid taken from a primary container (5) to circulate within the filtration unit, thus enabling the treatment of the patient's blood. There is further an infusion line (6) acting on the outlet line of the blood circuit, which is supplied by an auxiliary fluid container (7). The inlet line of the fluid circuit is equipped with at least an infusion branch (8) acting on the outlet line of the blood circuit so as to enable the intensive therapy machine to manage therapies with large exchange of fluids.

Abstract: Carboxylic acids comprising perfluoropolyether chains, of formula: T1-CFW1—O—Rf—CFW2-T2 ??(I) wherein T1, T2, equal to or different from each other, are selected from the group formed of —CH2—B—Y—(COOH)n, —CH(CF3) O—Y(COOH)n, —F, —CF3, —C2F5, —(C2F4)Cl , wherein B=—O—or —S—; Y=C1—C20 alkylene chain, n=1-4; with the proviso that at least one of the two end groups T1, T2 be —CH2—B—Y—(COOH)n, —CH(CF3)O—Y(COOH)n; W1W2, equal to or different from each other, are —F or —CF3; Rf is a (per)fluoropolyoxyalkylene chain formed of one or more repeating units, statistically distributed along the chain, having a number average molecular weight in the range 500-10,000.

Abstract: A process for preparing perfluoropolyethers having at least one —CH2OH or —CH(CF3)OH end group by reaction of the corresponding pefluoropolyethers having at least one carboxylic —COOH or ketonic —(CF3)C═O end group with gaseous hydrogen, between 80° C. and 140° C., in the presence of hydrogenation catalysts.

Abstract: The invention relates to support element (4) comprising a main body (6) having a front wall (25) and a peripheral wall (32) projecting away from the front wall. The front wall and the peripheral wall define a housing compartment (33) designed to receive a fluid distribution circuitry cooperating with a treatment unit for defining an integrated blood treatment module.

Abstract: The support device for bags, applicable in machines for extracorporeal blood treatment or in machines for renal failure treatment, comprises a base body (2) and a support element (3) associated to the base body in such a way as to be displaceable with respect to the base body between at least one operative loading position and an operative work position. In particular the support element is telescopically engaged to the base body and is slidable along a predetermined movement direction (4). The special configuration of the support device enables an easy loading of the machine and a subsequent optimal control of the machine stability.

Abstract: The invention relates to an integrated blood treatment module (1) comprising a support element (4) and a fluid distribution circuitry associated thereto; the distribution circuitry comprises at least a blood line (44), a portion of which is secured to the support element and defines with the latter at least a U-shaped tube length (44a) designed to cooperate, when in use, with a respective pump (3a). There are then further fluid lines (45, 48, 50, 51) fastened to the support element and defining each at least a U-shaped tube length (45a, 48a, 50a, 51a) with respect to said element and each designed to cooperate, when in use, with a respective pump (3b, 3c, 3d, 3e). The support element has a first zone (274) in which the portion of the blood line is secured, and at least a second zone (275) opposite said first zone, to which all the corresponding further tube lengths are fastened.

Abstract: Process for the perfluoropolyether preparation having reactive end groups —CH2NH2, —CHO, —CH2OH, by reduction of the corresponding perfluoropolyethers having —CN, —COCl, —CHO end groups by using gaseous hydrogen in the presence of a catalyst constituted by Pd, Rh, or Ru, supported on solid metal fluorides, at a temperature from 20° C to 150° C and under a pressure between 1 and 50 atm.

Abstract: A process for the preparation of perfluoropolyethers of formula:

Abstract: Hydrofluoroethers of formula:

Abstract: Process for obtaining mixtures of phosphoric mono- and diesters having the formula: [Rf—CF2—(CH2)q—Z]w—P(O)(OH)3−w  (I) HO—[OH(O)P—Z—(CH2)q—CF2—O—Rf—CF2—(CH2)q—Z]v—P(O)(OH)2  (II) wherein: w=1-2; v=1-6; q=1-20; Z=O(C2H4O)p—, O(CH2)n—O—, O(C3H6O)p—, S(C2H4O)p—, S(C3H6O)p—; n=1-20; p=1-5; Rf represents a (per)fluoropolyether chain; Rf in formula (I) is a monofunctional perfluoropolyether chain wherein the chain end group is selected from: CF3O—, C2F5O—, C3F7O—, Cl(C3F6O)—, H(C3F6O)—.

Abstract: Cyclic phosphazene compounds of formula (I): 1

Abstract: A process to obtain fluoropolyoxyalkylenes having the structure: T—O—(CF2CF(CF3)O)n−1—(CF(CF3)O)m—CF2—CH2OH  (I) wherein: T=C1-C3 perfluoroalkyl containing one Cl atom; n=an integer from 1 to 15; m/n=0-0.5, m+n such to have a number molecular weight in the range 280-4,000; said process comprising: a) the gradual addition of a metal hydride in admixture with a solvent to an ester precursor having the structure T—O—(CF2CF(CF3)O)n−1—(CF(CF3)O)m—CF2—COOR  (II)  wherein R=C1-C20 alkyl, or aromatic, cycloalkyl or heterocyclic residue, b) the hydrolysis of the reaction mixture obtained in step a) with an aqueous acid solution, the subsequent separation from the obtained organic phase of the compounds of structure (I).

Abstract: A process for preparing perfluoropolyoxyalkylenes with hydroxyl end groups having structure: T1—CFW1—O—Rf—CFW2—T2  (I) wherein: T1, T2, are selected from —CH2OH, —F, —CF3, —CF2CF3 with the proviso that at least one of T1 and T2 is —CH2OH; W1 and W2 are selected from F, CF3; Rf is a perfluoropolyoxyalkylene chain having a number average molecular weight 500-10,000 comprising one or more units of the type —CF2CF2O—, —CF2O—, —C3F6O—, —CF2(CF2)zCF2O— (z=1,2); —CR4R5CF2CF2O— with R4 and R5 selected from H, Cl, perfluoroalkyl group; said process comprising the following steps: a) adding an ester precursor having structure (I) and T1, T2 end groups selected from —F, —CF3, —CF2CF3, —COOR (R=linear or branched alkyl group having a number of C atoms from 1 to 5), with the proviso that at least one of T1 and T2 is —COOR, in a reaction mixture f